Market capitalization | SEK759.10m |
Enterprise Value | SEK680.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.64 |
P/S ratio (TTM) P/S ratio | 12.98 |
P/B ratio (TTM) P/B ratio | 2.19 |
Revenue growth (TTM) Revenue growth | 63.55% |
Revenue (TTM) Revenue | SEK58.48m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
Dec '24 |
+/-
%
|
||
Revenue | 58 58 |
64%
64%
|
|
Gross Profit | 19 19 |
142%
142%
|
|
EBITDA | -114 -114 |
2%
2%
|
EBIT (Operating Income) EBIT | -133 -133 |
0%
0%
|
Net Profit | -119 -119 |
11%
11%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.
Head office | Sweden |
CEO | Philip Siberg |
Founded | 1999 |
Website | www.senzime.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.